Loyau J, Monney T, Montefiori M, Bokhovchuk F, Streuli J, Blackburn M, et al. Biparatopic binding of ISB 1442 to CD38 in trans enables increased cell antibody density and increased avidity. MAbs. 2025;17:2457471 pubmed publisher

Richardson S, Kgagudi P, Manamela N, Kaldine H, Venter E, Pillay T, et al. Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages is reduced in convalescent sera regardless of infecting variant. Cell Rep Med. 2023;4:100910 pubmed publisher

Liu L, Iketani S, Guo Y, Reddem E, Casner R, Nair M, et al. An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses. Sci Transl Med. 2022;14:eabn6859 pubmed publisher

Lee A, Jin H, Masudul Haque M, Kim H, Jung H, Park J, et al. Synergism of a novel MCL‑1 downregulator, acriflavine, with navitoclax (ABT‑263) in triple‑negative breast cancer, lung adenocarcinoma and glioblastoma multiforme. Int J Oncol. 2022;60: pubmed publisher

Keeton R, Richardson S, Moyo Gwete T, Hermanus T, Tincho M, Benede N, et al. Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner. Cell Host Microbe. 2021;29:1611-1619.e5 pubmed publisher